In patients with LVNC and HFrEF, the addition of SGLT2 inhibitor therapy to concomitant heart failure treatment appears to be associated with favorable clinical outcomes and may contribute to reverse remodeling of the failing myocardium in this patient population. Here, SLC5A2 is linked to left ventricular noncompaction.